While antibodies targeting PD-1 or PD-L1 have shown remarkable and long-lasting clinical effectiveness in some individuals with NSCLC, a significant number of patients who initially respond will eventually experience relapse due to acquired resistance (110). Here, CD274 is linked to non-small cell lung carcinoma.